Email: cspc@cspc.cn

Contact Us
EN

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT PERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL

VOLUNTARY ANNOUNCEMENT PERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL

May 14, 2024

VOLUNTARY ANNOUNCEMENTPERAMIVIR INJECTION OBTAINS DRUG REGISTRATION APPROVAL_00.png

Previous: VOLUNTARY ANNOUNCEMENT RECOMBINANT FULLY HUMAN ANTI-βKlotho MONOCLONAL ANTIBODY DRUG (JMT202) OBTAINS CLINICAL TRIAL APPROVAL

Next: CSPC Re-selected into TOP 25 Global Pharmaceutical Companies by Pipeline Size

Contact Us

Phone:

+86 311 8703 7015

Email:

cspc@cspc.cn

Products

Science

About Us

Legal terms Privacy protection
Copyright © CSPC Pharmaceutical Group Co., Ltd. All Rights Reserved |

Wechat